Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.
Ben Bergo
Advertisement
Articles by Ben Bergo
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
South Korea's MFDS receives NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia
2
Interventional glaucoma: Redefining the optometrist’s role in modern glaucoma management
3
Fitting the future: How technology is refining specialty lens care
4
.png "Optometry Times"){kind=logo}
